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Transforming growth factor 1 (TGF-1) is a pleiotropic factor involved in the regulation of extracellular matrix (ECM) synthe-
sis and remodeling. In search for novel genes mediating the action of TGF-1 on vascular ECM, we identified the member of the
lysyl oxidase family of matrix-remodeling enzymes, lysyl oxidase-like 4 (LOXL4), as a direct target of TGF-1 in aortic endothe-
lial cells, and we dissected the molecular mechanism of its induction. Deletion mapping andmutagenesis analysis of the LOXL4
promoter demonstrated the absolute requirement of a distal enhancer containing an activator protein 1 (AP-1) site and a Smad
binding element for TGF-1 to induce LOXL4 expression. Functional cooperation between Smad proteins and the AP-1 complex
composed of JunB/Fra2 accounted for the action of TGF-1, which involved the extracellular signal-regulated kinase (ERK)-
dependent phosphorylation of Fra2. We furthermore provide evidence that LOXL4 was extracellularly secreted and significantly
contributed to ECM deposition and assembly. These results suggest that TGF-1-dependent expression of LOXL4 plays a role in
vascular ECM homeostasis, contributing to vascular processes associated with ECM remodeling and fibrosis.
Transforming growth factor  (TGF-) is a pleiotropic factorwith important roles during embryonic development and in
the regulation of tissue homeostasis (1). TGF- responses initiate
by binding to and activating specific type I and II kinase receptors.
Signaling fromactivated receptors propagates by phosphorylation
of cytoplasmic mediators belonging to the Smad family, which
translocate to the nucleus, acting as transcription factors. In addi-
tion to the canonical Smad pathway, alternative, non-Smad path-
ways participate in TGF- responses and serve as nodes for cross
talk with, for example, the mitogen-activated protein kinase
(MAPK) family (2).
TGF- has been shown to be a key regulator of extracellular
matrix (ECM) synthesis and remodeling. Specifically, TGF- has
the ability to induce the expression and deposition of ECM pro-
teins, as well as to stimulate the production of protease inhibitors
that prevent their enzymatic breakdown (3). TGF- participates
in the pathogenesis of many cardiovascular diseases, including
hypertension, restenosis, atherosclerosis, cardiac hypertrophy,
heart failure, and aortic aneurysms (4). A common observation in
a number of vascular disorders is the alteration of the biomechani-
cal properties, which is a consequence of increased ECM stiffness
and subsequent loss of elasticity (5–7). Therefore, the ECM seems
to be central to understand the contribution of TGF- to the
pathogenesis of vascular diseases.
Collagens and elastin, the main ECM components of the vas-
cular matrix, are organized into supramolecular complexes form-
ing fibers and network-like structures (8). The assembly of colla-
gen fibrils and tropoelastin monomers is stabilized by the
formation of covalent associations. Lysyl oxidases (LOX) consti-
tute a family of enzymes which catalyze the conversion of lysine
and hydroxylysine groups into highly reactive aldehydes, which
eventually condense to form a variety of inter- and intrachain
cross-linkages (9). To date, five LOX enzymes have been identified
(LOX and LOX-like 1 to LOX-like 4), characterized by sharing the
conserved C-terminal copper binding and catalytic domains and
the unique N-terminal domains that determine individual roles.
LOX family members are essential factors for the maturation of
the ECM as evidenced in mouse models deficient in LOX and
LOXL1, which show aortic malformations (10, 11). The precise
functions and catalytic activities on elastin and collagen substrates
of the remaining members of the LOX family (LOXL2 to -4) are
not yet well understood.
In this work we identified the genes upregulated by TGF-1 in
bovine aortic endothelial cells, with particular emphasis on those
associated with the ECM and therefore potentially involved in
ECM homeostasis. We report LOXL4 as a direct target of TGF-1
signaling and describe the characterization of the molecular
mechanism utilized by TGF-1 to induce its expression. We also
provide evidence that LOXL4 is extracellularly secreted and sig-
nificantly contributes to ECM deposition. These data suggest that
TGF-1-dependent expression of LOXL4 can play a role in vas-
cular ECM homeostasis, with potential implications in vascular
pathologies associated with matrix remodeling and fibrosis.
MATERIALS AND METHODS
Cell culture.Primary bovine aortic endothelial cells (BAEC)were isolated
from thoracic aortas andmaintained in culture using previously described
methods (12). Mouse aortic endothelial cells (MAEC) were purchased
fromAngio-Proteomie (Boston,MA) and cultured according to theman-
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ufacturer’s instructions. Smad3 knockout andwild-type embryonic fibro-
blasts (MEF) were isolated from newborn mice and kept in culture using
standard procedures (13). Tetracycline (Tet)-inducible human embry-
onic kidney 293 (HEK 293) cells stably expressing LOXL4-green fluores-
cent protein (GFP) constructs were generated and maintained in culture
according to protocols previously published (14).
RNA expression by quantitative PCR and microarray analysis. For
RNA experiments, BAEC orMAEC were cultured in 100-mm cell culture
dishes and treated with 5 ng/ml TGF-1 (R&D Systems, Minneapolis,
MN). Total RNA was isolated by guanidinium thiocyanate/phenol-chlo-
roform extraction (15). cDNAwas synthesized from1g of RNAusing an
iScript cDNA synthesis kit, and quantitative PCR for the detection of LOX
isoforms or Fra2 mRNA was performed using iQ SYBR green Supermix
and specific primers (see Table S1 in the supplemental material) in a
CFX96 thermocycler (Bio-Rad, Hercules, CA). Relative mRNA expres-
sion was determined using the glyceraldehyde 3-phosphate dehydroge-
nase gene as a housekeeping gene according to the CT method (16).
cDNA microarray analysis was carried out using a GeneChip bovine
array (Affymetrix, Santa Clara, CA) containing 24,027 probe sets repre-
senting over 23,000 transcripts (including approximately 19,000UniGene
clusters). The purity and integrity of total RNAwere checkedwith anRNA
Bioanalyzer (Agilent 2100). RNA labeling, hybridization, scanning, and
analysis were performed in the Genomics Unit of the Centro Nacional de
Biotecnología (Madrid, Spain) according to the manufacturer’s instruc-
tions. Genes showing statistically significant expression changes in re-
sponse to TGF-1 exposure were identified by using a cutoff value of 2.
Western blot analyses. For protein studies, bovine aortic endothelial
or HEK 293 cells were cultured in 100-mm cell culture dishes and pro-
cessed essentially as previously described (12). Briefly, cells were washed
with phosphate-buffered saline (PBS) and lysed with 300 l Tris-SDS
buffer (60 mM Tris-HCl [pH 6.8], 2% sodium dodecyl sulfate [SDS]) to
obtain total cell lysate. Protein concentrations were determined with the
bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, Rockford,
IL). Equal amounts of protein (50 g) were separated on 7.5% SDS-
polyacrylamide gels, and fractioned proteins were transferred onto nitro-
cellulose membranes at 12 V for 50 min in a semidry Trans-Blot Turbo
system (Bio-Rad). Membranes were blocked by incubation for 1 h with
3% bovine serum albumin (BSA) in PBS containing 0.5% Tween 20, and
antigens were detected using specific primary antibodies (anti-LOXL4
[1:2,000, polyclonal, generated in our own laboratory by rabbit immuni-
zation with the C-terminal peptide ELSQEQEQRLRN, not conserved in
the remaining LOX isoforms but highly homologous among bovine,
mouse, and human LOXL4], anti--actin [1:20,000,monoclonal; Sigma],
anti-Fra2 [1:1,000, rat antibody generated in our own laboratory using a
histidine-tagged mouse full-length Fra2 protein], anti-Flag [1:2,000,
mouse monoclonal from Sigma], anti-JunD [1:1,000, rabbit polyclonal;
Santa Cruz], anti-JunB [1:1,000, rabbit polyclonal; Santa Cruz], anti-c-
Jun [1:1,000, rabbit polyclonal; Santa Cruz], anti-extracellular signal-reg-
ulated kinase [anti-ERK] total [p44/42 MAPK] [1:2,000, rabbit poly-
clonal; Cell Signaling], anti-phospho-ERK [phospho-p44/42 MAPK,
T202/T204] [1:1,000, rabbit polyclonal; Cell Signaling], and anti-GFP [1:
2,000, mousemonoclonal; Roche]). Blots were then developed and quan-
tified using corresponding IRDye 680- and IRDye 800-labeled secondary
antibodies with the Odyssey infrared imaging system (Li-Cor).
5=RACE.Todefine the transcription initiation site of the LOXL4 gene,
5= rapid amplification of cDNA ends (5= RACE) analysis was performed
using the SMART RACE cDNA amplification kit (Clontech, Mountain
View, CA). Briefly, total RNA from BAEC incubated with TGF-1 was
reverse transcribed in order to generate a first-strand cDNA suitable for 5=
RACE using SMART technology. A universal primer and a gene-specific
primer (see Table S1 in the supplemental material) were then used for the
generation of the 5=-end product. PCR fragments were analyzed by aga-
rose electrophoresis and visualized with ethidium bromide staining. The
resulting bands were excised from the gel, purified using the Geneclean
Turbo kit (MP Biomedicals, Santa Ana, CA), and TA cloned into pCR2.1
(Life Technologies, Carlsbad, CA). A significant number of Escherichia
coli colonies were picked, grown up, and analyzed by sequencing using
M13 reverse and forward primers.
Construction of LOXL4 gene promoter reporter constructs and cell
transfection. Analysis of LOXL4 gene transcriptional activity was per-
formed by luciferase reporter gene studies using genomic fragments of the
LOXL4 gene. Human LOXL4 promoter fragments were obtained by re-
striction cutting from clone RP11-34A14 on chromosome 10 containing
complete LOXL4 gene (BACPAC resources; Children’s Hospital Oakland
Research Institute [CHORI]). Preliminary attempts to generate by PCR
fragments of the LOXL4 promoter covering about 4 kb of 5= flanking
sequence and the complete exon 1 using bovine and mouse genomic
DNAswere unsuccessful, likely due to the presence of a high GC sequence
in the proximal promoter. Therefore, PCR assays were designed to gener-
ate the corresponding bovine and mouse LOXL4 promoter fragments
upstream from the high-GC segment, and proximal promoter sequences
were obtained by chemical synthesis (inserts in pBlueScript vector [Epoch
Life Sciences, Missouri City, TX]) (see Table S2 in the supplemental ma-
terial). Luciferase cassettes under the control of the LOXL4promoterwere
generated by assembly of upstream PCR fragments and synthetic proxi-
mal sequences into pGL3 vector (Promega, Madison, WI) by standard
cloning procedures. 5= deletion constructs of the bovine LOXL4 promoter
were generated by PCR and assembled into the luciferase reporter proxi-
mal promoter plasmid as described above. A distal fragment of the bovine
LOXL4 promoter containing AP-1 and Smad binding elements (113 bp)
was cloned in front of a cassette composed of a constitutive simian virus 40
(SV40) promoter fused to a luciferase gene (pGL3-Promoter; Promega)
or assembled to the proximal promoter luciferase vector in order to ana-
lyze its potential enhancer capacity. Reporter luciferase constructs of the
bp3870 LOXL4 promoter with specific mutations in AP-1 and in Smad
binding sites were generated by PCR-based site-directed mutagenesis as
previously described (12). The AP-1 site TGAGTCA was replaced by
GTAGTCA. Smad binding elements were mutated as follows: the SmadA
CAGA was replaced by TAAT, and the SmadB GTCTG was changed to
ATGTA. LOXL4 promoter constructs with a specific mutation in the Sp1
site (GGGGGCGGGG changed to GTTTTCGGGG) were obtained by
chemical synthesis (Epoch Life Sciences). All constructs were verified by
sequencing.
The vectors expressing the Smad3 and Smad7 transcription factors
under the control of strong constitutive cytomegalovirus (CMV) promot-
ers were kindly provided by Liliana Attisano (Toronto, Canada) and Aris-
tidis Moustakas (Uppsala, Sweden), respectively. Mammalian expression
vectors for Sp1 and Sp3 were kindly provided by Guntram Suske (Mar-
burg, Germany). Mouse Fra2 cDNA was excised from pBabe-Fra2 plas-
mid and cloned into pcDNA3 (CMV promoter; Life Technologies) (17).
A site-directed mutagenesis approach was used to generate a Fra2 expres-
sion vectorwith aC-terminal Flag tag (pcDNA3-Fra2-Flag) and, from this
construct, Fra2-Flag phosphorylation mutants with inactivating muta-
tions threonine to nonphosphorylatable alanine (T¡A) and phosphomi-
metic mutations replacing threonine by glutamic acid (T¡E) in residues
T263 and T274 (see Table S3 in the supplemental material). Constructs
for the overexpression of tethered JunB/Fra2, JunD/Fra2, and c-Jun/Fra2
dimers have been previously described (18).
DNA constructs were transiently transfected into BAEC, MAEC, and
wild-type or Smad3 knockout mouse embryonic fibroblasts on 24-well
plates (60 to 70% confluence), and promoter activity was estimated by
luminometry as described previously, using the pRL-CMV plasmid (con-
taining a Renilla luciferase gene under the control of the CMV promoter)
for normalization purposes (12)
Comparative genomic DNA analysis was performed by using the
Mulan multiple-alignment server (http://mulan.dcode.org) available at
the National Center for Biotechnology Information DCODE server (ECR
browser; http://www.dcode.org/) (19). LOXL4-orthologous sequences
from Homo sapiens, Mus musculus, Rattus norvegicus, Canis familiaris,
Felis catus,Bos taurus,Pongo pygmaeus,Pan troglodytes, andEquus caballus
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were obtained from the ENSEMBL genome database (http://www
.ensemble.org/). The CPGPlot program was used to detect CpG-rich re-
gions that may correspond to potential CpG islands. The ClustalW2 pro-
gram was used to align protein sequences from Fra2 and c-Fos orthologs
in order to screen for evolutionary conserved MAPK phosphorylation
sites (http://www.ebi.ac.uk).
ChIP. Chromatin immunoprecipitation (ChIP) experiments were
performed using a commercially available kit (Pierce agarose ChIP kit;
Thermo Fisher Scientific) according to the manufacturer’s instructions.
Briefly, cells were fixedwith 1% formaldehyde (Calbiochem, La Jolla, CA)
for 10min at room temperaturewith swirling. Glycinewas added to a final
concentration of 0.125 M, and the incubation was continued for an addi-
tional 5 min. Cells were washed twice with ice-cold PBS, harvested by
scraping, pelleted, and resuspended in 100 l of lysis buffer containing
protease inhibitors. Samples were centrifuged and the nuclear pellet re-
suspended in 100l ofmicrococcal nuclease (MNase) solution. Digestion
proceeded for 15 min at 37°C with occasional mixing. Afterwards, the
reaction was stopped, samples were centrifuged, and supernatants were
saved as digested chromatin for immunoprecipitation. After removal of a
control aliquot (input), samples were incubated at 4°C overnight with
anti-Smad2/3 (mouse monoclonal; BD Transduction Laboratories,
Franklin Lakes, NJ), anti-Fra2 (in-house, rat), or negative-control IgG.
Protein A/G Plus agarose beads were then added, incubated for 1 h, and
then extensively washed before chromatin was released by proteinase K
digestion and DNA was further recovered using spin columns. Purified
DNA was used for amplification of a region of 104 bp located at the
upstream enhancer by real-time quantitative PCR (see Table S4 in the
supplemental material). Quantities of target DNA in the ChIP and input
samples were determined based on a standard curve and expressed as
percentage of input after IgG background subtraction.
EMSA and oligonucleotide pulldown experiments. After different
treatments, nuclear extracts were prepared according to a procedure de-
scribed previously (20). Briefly, cell plates were washed once with ice-cold
PBS and scraped in the same medium. Upon centrifugation, they were
resuspended in 10 mMHEPES (pH 7.9), 10 mMKCl, 0.1 mM EDTA, 0.1
mM EGTA, 1 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl
fluoride, and 1 g/ml each of leupeptin, aprotinin, and pepstatin A
(Sigma). After 15 min of incubation on ice, Nonidet P-40 was added to a
final concentration of 0.5% and cells were vortexed for 10 s. Then nuclei
were sedimented by centrifugation for 5 min at 14,000  g. The nuclear
pellets were extracted by shaking on ice for 30 min in 20 mMHEPES (pH
7.9), 400mMNaCl, 1mMEDTA, 1mMEGTA, 1mMDTT, and protease
inhibitors as described above. After centrifugation, nuclear debris was
discarded by centrifugation at 14,000 g for 5 min, and nuclear extracts
were stored at80°C. Protein contentwas determined using the Bradford
method (Bio-Rad). Constructs for bacterial recombinant expression of
the glutathione S-transferase (GST) fusion proteins GST-Smad2, GST-
Smad3, and GST-Smad4 were kindly provided by Liliana Attisano (To-
ronto, Canada). Fusion proteins were expressed in E. coli and purified as
described previously (12). JunB/Fra2 forced dimers, wild type or with
mutations in residues T263 and T274, were prepared in vitro using the
TNT rabbit reticulocyte coupled transcription-translation system (Pro-
mega). JunB/Fra2 protein expression was checked by Western blot anal-
ysis using anti-JunB antibody.
Electrophoretic mobility shift assays (EMSA) with nuclear extracts (4
g), purified GST fusion forms (0.1 to 1g), or equivalent amounts of in
vitro-synthesized proteins were performed as described previously using
infrared-labeled oligonucleotides for the AP-1 or the Smad binding sites
(see Table S5 in the supplemental material) (12). Free oligonucleotides
and DNA-protein complexes were visualized with the Odyssey infrared
imaging system (Li-Cor). For competition experiments, unlabeled oligo-
nucleotides corresponding to wild-type Smad and AP-1 binding sites, or
including specificmutations, were added to the incubationmixture in a 1-
to 100-fold excess.
Oligonucleotide pulldown experiments were designed in order to
identify and characterize proteins interacting with the DNA sequence
containing the AP-1 and Smad binding sites. 5=-biotinylated wild-type
and mutated AP-1/SmadB DNA fragments corresponding to positions
3866/3754were generated by PCRusing the corresponding 5=-biotin-
ylated forward primer and wild-type and mutated reverse primers (see
Table S4 in the supplemental material), purified using Geneclean (Turbo
kit MP Biomedicals), and verified by electrophoresis and ethidium bro-
mide staining. For the reaction, 100 g of nuclear extracts from bovine
aortic endothelial cells incubated with or without TGF-1 was incubated
for 20min at 4°C in a volumeof 100l of binding buffer [10mMTris-HCl
(pH 7.4), 50 mM NaCl, 1 mM MgCl2, 5 mM DTT, and 5% glycerol and
containing 0.02 mg/ml of poly(dI-dC) (General Electric, Little Chalfont,
United Kingdom)] with 5=-biotinylated wild-type and mutated oligonu-
cleotides. Afterwards, 50l of SoftLink soft release avidin resin (Promega;
1:1 slurry, equilibrated according to the manufacturer’s instructions) was
added and the mixture further incubated for 1 h at 4°C with occasional
shaking. Beads were then washed five times with 500 l of binding buffer
without poly(dI-dC). Retained proteinswere finally eluted from the beads
by addition of 50 l Laemmli buffer and centrifugation at 14,000  g
for 15 min, fractioned by SDS-PAGE, and visualized by Coomassie blue
staining.
Bands corresponding to candidate proteins were dissected and gel
pieces digested in situ with sequencing-grade trypsin (Promega) as previ-
ously described (21). Mixtures of proteolytically generated peptides were
analyzed by reverse-phase liquid chromatography–tandem mass spec-
trometry (RP-LC-MS/MS) in an Agilent 1100 system coupled to a linear
ion trap LTQ-Velos mass spectrometer (Thermo Fisher Scientific). The
peptides were separated using a 0.18- by 150-mm Bio-Basic C18 RP col-
umn (Thermo Fisher Scientific) operating at 1.8 l/min. Peptides were
eluted using a 35-min gradient from 5 to 40% solvent (solvent A, 0.1%
formic acid in water; solvent B, 0.1% formic acid and 80% acetonitrile in
water). Electrospray ionization (ESI) was done using amicrospray “metal
needle kit” interface (Thermo Fisher Scientific). Peptides were detected in
survey scans from 400 to 1,600 amu (1 microscan), followed by five data-
dependent MS/MS scans (Top 5), using an isolation width of 2 U (in
mass-to-charge ratio units), a normalized collision energy of 35%, and
dynamic exclusion applied during 30-s periods. Peptide identification
from raw data was carried out with the SEQUEST algorithm (Proteome
Discoverer 1.2; Thermo Fisher Scientific) using the Bos taurus UniProt
database. The following constraints were used for the searches: tryptic
cleavage after Arg and Lys, up to twomissed cleavage sites, and tolerances
of 1 Da for precursor ions and 0.8 Da for MS/MS fragment ions. The
searches were performed allowing optional Met oxidation and Cys carb-
amidomethylation. Searching against a decoy database (interpreted decoy
approach) was performed using a false discovery rate of0.01. The com-
plete proteomic analysis was carried out in the Centro de BiologíaMolec-
ular Severo Ochoa Protein Chemistry Unit, a member of ProteoRed net-
work (www.proteored.org).
GST-Fra2 pulldown assays. Mouse Fra2 cDNA sequence was ampli-
fied from plasmid pBabe-Fra2 with primers containing adequate restric-
tion sites for cloning into the pGEX-2T vector (GE Healthcare, Little
Chalfont, Buckinghamshire, United Kingdom) (see Table S6 in the sup-
plemental material). Specific mutations in residues T263 and T274 were
introduced by site-directed mutagenesis using primers shown in Table S3
in the supplementalmaterial. Fusion proteinswere expressed inE. coli and
purified as described previously (12). For pulldown experiments, equiva-
lent amounts of GST-Fra2 beads were incubated with total extracts from
bovine aortic endothelial cells for 2 h at room temperature with rocking.
The beads were thenwashed four times with PBS and then resuspended in
Laemmli buffer for SDS-PAGE and Western blot analysis of endogenous
JunB and recombinant Fra2.
Adenoviral infection and siRNA-mediated inhibition of gene ex-
pression. Recombinant-deficient human adenovirus type 5 (dE1/E3)
overexpressing a dominant negative form of AP-1 (Adv-TAM67) and
empty vector adenovirus (Adv-Null) were purchased fromVector Biolabs
Busnadiego et al.
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(Philadelphia, PA). Mouse Fra2 and bovine LOXL4 cDNA (the former
excised from pcDNA3-Fra2 and the latter generated by reverse transcrip-
tion coupled to PCR using total RNA from TGF-1-incubated bovine
aortic endothelial cells) were cloned into a suitable shuttle vector to gen-
erate adenoviral constructs for mammalian overexpression (Vector Bio-
labs). Adenoviruses were amplified using embryonic kidney cell line HEK
293. Briefly, HEK 293 cells were cultured until the monolayer was 90%
confluent and then infected with cytopathic levels of adenoviruses for 48
h. For purification of adenoviruses, infected cells and supernatants were
taken and centrifuged at 1,000  g for 5 min. Supernatants were dis-
carded, and cell pellets were lysed with three freezing-thawing cycles to
release virus particles. The viruses were then purified using the Adeno-X
Maxi purification kit from Clontech (Mountain View, CA) according to
the manufacturer’s instructions. Virion concentrations were determined
using the Adeno-X-Rapid titer kit from Clontech, and viral stocks were
stored in aliquots at 80°C. For adenoviral infection of primary bovine
aortic endothelial cells, these were seeded in 100-mm culture dishes and
exposed to adenoviral constructs for 24 h. Cells were then washed and
incubated in serum-free medium for an additional 24-h period. In some
experiments, infected cells were transfected with DNA plasmid during
this 24-h period. Cells were then finally stimulated with TGF-1 or left
untreated as indicated.
Specific small interfering RNAs (siRNAs) for the inhibition of the
expression of bovine Fra2, c-Jun, JunB, and JunD and a nontargeting
control were purchased from Ambion (Silencer Select siRNA; Life Tech-
nologies) (see Table S7 in the supplemental material). Cell transfections
were performed in 6-well plates as described above.
Immunofluorescence microscopy. Fluorescence microscopy was
performed as previously described (22). Briefly, primary bovine aortic
endothelial cells were seeded onto 24-well plates containing 10-mm-di-
ameter glass coverslips. After the corresponding treatment, cells were
fixed with 4% paraformaldehyde in PBS for 10 min and then permeabil-
ized with 0.2% Triton X-100 in PBS for 5 min at room temperature. Cells
were washed with PBS, blocked with 1% BSA in PBS for 1 h, and then
incubated overnight at 4°C with primary antibodies (anti-Fra2 [1:200, rat
antibody described above], anti-GFP [1:200, mouse monoclonal from
Roche], and anticalnexin [endoplasmic reticulum [ER] marker, 1:200,
rabbit polyclonal; Stressgen, SanDiego, CA), followed by the correspond-
ing fluorescent secondary antibodies. For collagen IV staining (anti-col-
lagen IV [1:200, rabbit polyclonal; Novotec, Lyon, France), cells were
fixed with cold methanol for 5 min and blocked with 10% goat serum for
20 min after three washes with PBS before the incubation with the anti-
body. Nuclear staining was performed with DAPI (4=,6=-diamidino-2-
phenylindole) (Sigma). Cell fluorescence was visualized by microscopy
with a Nikon Eclipse T2000U (Nikon, Amstelveen, The Netherlands) or
an LSM710 laser confocal microscope (Carl Zeiss, Overkochen, Ger-
many).
Mammalian expression of recombinant LOXL4-GFP isoforms. To
study subcellular localization and potential extracellular secretion of
LOXL4, we generated constructs for the overexpression of a fusion pro-
tein of bovine LOXL4 and green fluorescent protein (LOXL4-GFP). For
that purpose, LOXL4 cDNA was cloned into pEGFP-N1 vector (Life
Technologies) to yield full-length LOXL4-GFP. Deletion mutants from
this construct lacking the scavenger receptor cysteine-rich (SRCR) do-
mains and the C-terminal catalytic region were generated by site-directed
mutagenesis (see oligonucleotide sequences inTable S8 in the supplemen-
tal material). These constructs were used for transient transfection in
primary aortic endothelial cells as described above. To generate stable
transfectants of HEK 293 cells overexpressing LOXL4-GFP isoforms,
LOXL4-GFP fragments were cloned into the pcDNA5/FRT/TO vector
(Life Technologies) to give pcDNA5/FRT/TO/LOXL4-GFP constructs.
These constructs were then cotransfected with the Flp recombinase ex-
pression plasmid pOG44 into the Flp-In T-Rex 293 cell line (Life Tech-
nologies). Cells of this line stably express the tetracycline (Tet) repressor
and contain a single integrated Flp recombination target (FRT) site. Flp
recombinase expression from the pOG44 vector mediates insertion of
pCDNA5/FRT/TO-based constructs into the genome at the integrated
FRT site through site-specific DNA recombination. After 48 h, cells were
selected with hygromycin B, and clones appeared after 10 to 15 days.
Isogenic pooled cloneswere expanded andused for experiments involving
induction by the Tet analog doxycycline (Dox). Expression of LOXL4-
GFP chimeras upon Dox incubation was checked by Western blotting
using anti-GFP antibodies as described above.
Detection of LOXL4 in the extracellular medium. The release of
LOXL4 to the extracellular medium was investigated in HEK 293 cells
overexpressing LOXL4-GFP isoforms. Cells were seeded on 100-mm cul-
ture dishes.When 90% confluence was reached, they were incubated with
5 ml of serum-free medium containing doxycycline (1 g/ml) for 48 h.
Cell supernatants were collected, centrifuged at 100,000 g for 1 h at 4°C,
and then concentrated down to 100 l using Amicon ultracentrifugal
filters (Ultracel-10K; Millipore, Billerica, MA) and further immunopre-
cipitated by incubation overnight at 4°C with anti-GFP antibody. After
addition of 50 l of SoftLink soft release avidin resin (Promega), samples
were incubated for 1 h at 4°C. Beads were then washed five times with
buffer and retained proteins eluted out from the beads by adding Laemmli
buffer. Supernatants were subjected to SDS-PAGE, fractioned proteins
transferred to nitrocellulose membranes, and GFP-immunoreactive
bands detected by Western blotting as described above.
In vitro collagen remodeling and lysyl oxidase activity assays. Con-
ditioned medium from primary bovine aortic endothelial cells incubated
with or without TGF-1 or infected with Adv-LOXL4 or control Adv-
Null was concentrated by means of Amicon ultracentrifugal devices as
described above. Type I collagen solution (2mg/ml) was mixed with con-
centratedmedium and incubated at 37°C for 30min. Additional medium
was added on top of the gelled collagen for further incubation at 37°C for
16 h. The gel was analyzed under confocal reflection microscopy in an
LSM710 laser confocal microscope (Carl Zeiss) as previously described
(23).
Cell supernatants were also assayed for lysyl oxidase activity using
diaminopentane andAmplex red as previously described (24). In a typical
assay, samples of 100 l of concentrated medium were mixed with the
reactionmixture containing 10mMdiaminopentane, 10MAmplex red,
and 1U horseradish peroxidase in 1.2Murea–0.05M sodium borate (pH
8.2) in the presence or absence of 0.5 mM -aminopropionitrile (BAPN),
an active-site inhibitor of lysyl oxidases. H2O2 release wasmeasured every
15min for a total period of 24 h at excitation and emission wavelengths of
525 and 580 to 640 nm, respectively, on a Glomax multidetection system
(Promega). Enzyme activities were expressed as fluorescence values, cor-
rected for background levels of H2O2 release determined in the reaction
mixture supplemented with BAPN. Recombinant human LOXL2, used as
a positive control for lysyl oxidase activity, was purchased from R&D
Systems.
Statistical analysis. Experimental data were analyzed using the un-
paired Student t test in the case of normal distribution of data or using
nonparametric tests as appropriate. TheP values obtained are indicated in
the figure legends when statistically significant (P 0.05).
Microarray data accession number.Themicroarray data are publicly
available at the National Center for Biotechnology Information Gene Ex-
pression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession
number GSE42932.
RESULTS
TGF-1 strongly induces LOXL4 expression in aortic endothe-
lial cells through Smad and AP-1. In order to gain insight about
the potential ECM-related TGF-1 target genes in the cardiovas-
cular system, we profiled mRNAs from bovine aortic endothelial
cells under basal conditions and incubated with TGF-1 for 24 h.
Comparing with control cells, it was found that TGF-1 exerted a
profound effect on global expression, with more than 500 genes
upregulated under our experimental conditions (GEO accession
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number GSE42932). A significant number of genes positioned at
the top of the list can be classified as ECM-related targets, includ-
ing several collagen isoforms as well as collagen-modifying en-
zymes (Fig. 1A). A candidate TGF-1 target gene, that for lysyl
oxidase-like isoform 4 (LOXL4), attracted our attention as it
showed the strongest induction, in addition to its relevance for
ECM synthesis and remodeling. Analysis of the ability of TGF-1
to modulate the expression of lysyl oxidase family members re-
vealed that only LOXL4 and, to a lesser extent, the canonical LOX
were upregulated in this cell model (Fig. 1B). Careful examination
of the time course response of the LOXL4 gene to TGF-1 showed
that mRNA and protein begin to accumulate at as early as 2 h of
incubation with the cytokine, indicating that LOXL4 might be a
direct target for the action of TGF-1 in the endothelium (Fig. 1C
and D).
To elucidate the transcriptional mechanism for the control of
LOXL4 expression by TGF-1, we isolated a genomic fragment of
the promoter of the bovine gene. Conflicting reports exist on the
position of the transcriptional start site and therefore on the pre-
cise location of the promoter in the human gene (25, 26). Addi-
tionally, experimental evidence about the site(s) for the initiation
of transcription in the bovinemodel has not been reported. There-
fore, we first endeavored to identify the transcription initiation
sites in the bovine LOXL4 gene by 5= rapid amplification of cDNA
ends (5= RACE). A major 5= RACE product was obtained and
sequenced, yielding several start sites tightly clustering around the
annotated site for the initiation of transcription located 121 nu-
cleotides upstream of the translation initiation codon ATG (see
Fig. S1 in the supplemental material). Based on this finding, a
genomic fragment of approximately 4 kb (3870/87) including
the 5= flanking sequence and complete exon 1 was generated and
cloned in front of a luciferase reporter gene to study the effect of
TGF-1. In a set of preliminary experiments, we tested this frag-
ment and also a pair of truncated constructs of 2.2 and 0.3 kb. As
shown in Fig. S2 in the supplementalmaterial, while the activity of
these truncated promoter fragments was not significantly modi-
fied by TGF-1 incubation, the cytokine induced a potent in-
crease in luciferase activity (5- to 6-fold at 24 h) in cells transfected
with the longest, 4-kb construct. These results indicate that a pro-
moter region between bp3870 and2266 contains the critical
elements to mediate the transcriptional activation of the gene.
We screened the bp3870/2266 promoter region for puta-
tive binding sites for Smad and AP-1 transcription factors, both of
which have been described to be important for the effect of
TGF-1 on gene expression (12, 27, 28). An upstream AP-1 con-
sensus site (TGAGTCA) and several elements identical or similar
to the Smad consensus sequence (CAGAC), either alone or in a
palindromic form, were identified by in silico analysis (see Fig. S3
FIG 1 LOXL4 is a TGF-1 target gene in aortic endothelial cells. (A) Panel of ECM-related genes showing significant expression changes (fold change,2) upon
24 h of TGF-1 (5 ng/ml) treatment, identified by genome-wide expression. (B) Quantitative PCR of LOX gene family members (LOX and LOXL1 to -4) in
TGF-1-stimulated BAEC. Values above the bars in parentheses indicate the induction rates with respect to basal levels. (C) LOXL4 mRNA expression as a
function of TGF-1 incubation time as assessed by quantitative PCR. (D) Time-dependent effect of TGF-1 on LOXL4 protein (representativeWestern blotting
and densitometric analysis of the LOXL4/-actin signal)., positive control of cells infected with LOXL4 adenovirus. Values are represented as fold induction
with respect to basal values (means	 standard errors of the means [SEM]; n
 3).
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in the supplemental material). Based on the location of these pu-
tative regulatory elements, we generated a set of 5= deletion lucif-
erase constructs and tested their inducibility by TGF-1. As
shown in Fig. 2A, the TGF-1 response observed with the3870/
87 fragment was eliminated as soon as a short segment of 113 bp
containing putative AP-1 and Smad elements was removed. In
fact, this fragment can be considered an enhancer, as it is able to
confer TGF-1 responsiveness to a core promoter in a manner
that is independent of its orientation and distance relative to the
RNA start site, as shown in experiments with constructs generated
in the context of its cognate proximal promoter and of the viral
SV40 promoter (Fig. 2B and C). In order to assess the relevance of
theAP-1 and Smad elements identified in this enhancer region, we
generated full promoter constructs (bp3870/87) with specific
mutations in these sites (AP-1, SmadA, and SmadB) and tested
their activity upon TGF-1 stimulation. As shown also in Fig. 2D,
the disruption of the AP-1 element and the downstream Smad
site, the consensus SmadB, either in individually or combined in
the same construct, caused a significant reduction in their ability
to respond to TGF-1. In contrast, the specific mutation of the
upstream Smad-like site (SmadA) did not show any significant
effect.
Multiple-sequence alignment analysis is a powerful approach
for identifying functional regulatory elements, such as exons or
enhancers. We used the Mulan multiple-alignment server (http:
//mulan.dcode.org) to analyze the promoter regions of several
mammalian orthologs of LOXL4 in order to evaluate the relevance
of the DNA elements identified in the present study and also to
screen for an additional control region(s) (19). As shown in Fig.
3A, at least three well-conserved regions were identified across
these genomes, namely, a short stretch at the proximal promoter,
a broader region in the central portion of the promoter fragment
used for comparison, and finally, an upstream region partially
overlapping the enhancer involved in the TGF-1 induction. Sur-
prisingly, rodent genomes differed from the rest of mammalian
genomes compared in this study, as they did not show significant
homology in the upstream enhancer. Careful examination of the
sequence of this DNA segment revealed that the consensus AP-1
site is not present in the equivalent regions from rat and mouse
(Fig. 3B), an observation that predicts that the LOXL4 gene may
not respond to TGF-1 in these mammalian species. To test this
hypothesis, the corresponding fragments of human and mouse
LOXL4 promoters were isolated and fused to a luciferase reporter
for analysis of their TGF--dependent transcriptional activity in
BAEC and MAEC. As shown also in Fig. 3C, human and bovine
LOXL4 promoters displayed significant TGF-1 inducibility in
both bovine andmouse cells. In contrast, the construct containing
themouse LOXL4 promoter was unresponsive to TGF-1 in both
bovine and mouse endothelial cells. Accordingly, LOXL4 gene
expression was not altered by TGF-1 in MAEC, whereas was
highly upregulated in BAEC (Fig. 3D). These results are consistent
with the analysis of conserved regions, and altogether the results
underscore the contribution of the AP-1 and Smad elements
within this enhancer region to the induction of LOXL4 expression
by TGF-1.
The well-conserved proximal promoter of the LOXL4 gene
lacks a TATA box, but it contains a GC-rich region that may cor-
respond to a potential CpG island. Using the CPGPlot program
(http://www.ebi.ac.uk), analysis of the proximal LOXL4promoter
from bp307 to87 revealed a CpG island that lies between bp
260 and29 (see Fig. S4A in the supplemental material). Sp1 is
a ubiquitous transcription factor that binds GC-rich sequences
that are present inmany CpG islands, and it is reported to prevent
their methylation (29). A consensus Sp1 site (GGGGGCGGGG)
has been also identified in the CpG island of the LOXL4 proximal
promoter (see Fig. S4A in the supplemental material). Site-di-
rected mutagenesis of this putative Sp1 binding site strongly re-
duced the basal activity of LOXL4 promoter without significantly
affecting the induction byTGF-1 (see Fig. S4B in the supplemen-
talmaterial). Accordingly, the overexpression of Sp1 familymem-
bers Sp1 and Sp3 increased both basal and TGF-1-stimulated
promoter activity (see Fig. S4C in the supplemental material),
indicating that the proximal promoter importantly contributes to
the basal transcription machinery but seems to be dispensable in
the induction by TGF-.
Smad and JunB/Fra2 transcription factors contribute to
TGF-1 induction of the LOXL4 gene. TGF- regulates gene ex-
pression through Smad-dependent and -independent pathways
FIG 2 Mapping of TGF-1-responsive elements within the LOXL4 promoter.
(A) TGF-1-dependent activity of luciferase constructs driven by 5= deletion
fragments of the LOXL4 promoter from bp 3870 to 304 transfected into
BAEC. A schematic representation of the bp 3900/2300 promoter se-
quence shows the position of putative AP-1 and Smad sites (white and black
boxes, respectively). (B and C) The3870/3756 promoter fragment is suf-
ficient to confer TGF-1 responsiveness to its cognate proximal promoter
(304/87) (B) and to a viral SV40 promoter (pGL3-Promoter) (C) in an
orientation-independent manner. (D) Specific point mutations in the bp
3870/87 LOXL4 promoter construct that alter Smad and AP-1 elements as
indicated were introduced and their TGF-1 inducibility measured by lumi-
nometry. TGF-1 induction rates are expressed as mean 	 SEM (n 
 3). *,
P  0.05 versus promoterless construct (A) versus 304/87 proximal
LOXL4 promoter (B), versus pGL3-Promoter (C), or versus the wild type (D),
in the absence of TGF-1.
TGF-1-Induced LOXL4 Regulates Matrix Remodeling
June 2013 Volume 33 Number 12 mcb.asm.org 2393
(30). To investigate the role of Smad familymembers in themech-
anism of LOXL4 upregulation by TGF-1, the activating Smad3
and the inhibitory Smad7 were overexpressed in BAEC and their
effect on LOXL4 promoter activity analyzed in luciferase assays.
Figure 4A shows that Smad3 potentiated, whereas Smad7 signifi-
cantly reduced, both basal and TGF-1-induced promoter activ-
ity. The implication of Smad3 was further confirmed by experi-
ments with mouse embryonic fibroblasts (MEF) isolated from
wild-type and Smad3 knockout embryos. As shown also in Fig. 4B,
TGF-1 activated the LOXL4 promoter in transfected wild-type
MEF, whereas it showed no effect on Smad3 knockout cells. TGF-
1-mediated induction of the LOXL4 promoter was recovered in
these cells upon reintroduction of Smad3.
On the other hand, the implication of AP-1 members was in-
vestigated by adenovirus-mediated overexpression of a dominant
negative form of AP-1 (TAM67) that binds to DNA but is not able
to transactivate (31). TAM67 dose dependently inhibited the in-
duction of LOXL4 expression by TGF-1 at the levels of both
mRNA and promoter activity (Fig. 4C and D).
EMSA and ChIP experiments were performed to detect and
characterize protein-DNA complexes at the LOXL4 promoter.
EMSA with nuclear extracts from cells under basal conditions
showed an AP-1 binding activity that was significantly increased
upon incubation with TGF-1 (see Fig. S5A and B in the supple-
mental material). The binding to this complex was competed out
by an excess of unlabeled AP-1 oligonucleotide but not by a mu-
tated one. Smad proteins bind to Smad sites with low affinity, and
this feature makes their detection by EMSA difficult (32). ChIP
using a specific Smad2/3 antibody successfully revealed the re-
cruitment of Smad factors to the enhancer region within the
LOXL4promoter in aTGF-1-dependentmanner (see Fig. S5C in
the supplemental material). Smad binding was further confirmed
by EMSA with the use of recombinant proteins. Recombinant
Smad4 and, to a lesser extent, Smad3 displayed strong binding
activity to a Smad probe (see Fig. S5D in the supplemental mate-
rial). In agreement with site-specific mutagenesis experiments, a
wild-type Smad probe or a probe with a specific mutation in the
Smad-like site, SmadA, efficiently competed out the binding ob-
served to recombinant Smad4 compared with a probe mutated in
the consensus SmadB (see Fig. S5E and F in the supplemental
material).
In an effort to identify the proteins involved in the regulation
of LOXL4 expression by TGF-1, a DNA pulldown assay was em-
ployed to isolate proteins that specifically and differentially bind
to a DNA sequence derived from the upstream enhancer. 5=-bio-
tinylated wild-type and mutated AP-1/SmadB DNA fragments
corresponding to positions 3870/3756 were exposed to nu-
clear extracts from BAEC incubated with or without TGF-1, and
DNA-bound proteins were separated by SDS-PAGE and visual-
ized by Coomassie blue staining (see Fig. S6A in the supplemental
material). A protein band of approximately 35 kDa was signifi-
cantly enriched in samples obtained from TGF-1-treated cells
and incubated with the wild-type oligonucleotide compared with
those incubated with the mutant DNA probe or isolated from
control cells. SEQUEST searches of LC-MS analyses of tryptic
peptides from the excised band showed that one of the proteins
identified corresponded to amember of the AP-1 family, FOS-like
antigen 2 (FOSL2) or Fra2 (see Fig. S6B andC in the supplemental
material).
Fra2 has recently evolved as an extremely interesting factor in
the context of vascular ECM remodeling and fibrosis (33–36). In
order to confirm the implication of Fra2 in the upregulation of
LOXL4 expression, we performed gain- and loss-of-function ex-
periments. Adenovirus-mediated overexpression of Fra2 potenti-
ated TGF-1-induced LOXL4 expression at the level of promoter
activity and protein (Fig. 5A). Fra2 overexpression also associated
with its binding to the enhancer region within the LOXL4 pro-
FIG 3 Analysis of conserved regions in the LOXL4 promoter across mamma-
lian genomes. (A) Comparative genomic analysis of the promoter regions of
several mammalian LOXL4 orthologs (Mulan multiple-alignment engine).
The graphical representation shows stacked-pairwise conservation profiles
for the 4-kb promoter region of the LOXL4 gene between the indicated
species and the reference bovine sequence. The color intensity of a con-
served region depends on the number of different species that contain the
region (the darker the color, the more conserved species). Only evolution-
arily conserved regions (ECR) present in at least six out of eight total
secondary species are highlighted in the alignment. Note that sequence
corresponding to proximal promoter from cat was not available in the
ENSEMBL database. (B) Multiple-sequence alignment of the most upstream
ECR, showing the locations of the AP-1 site (blue) and Smad binding elements
(red). (C) TGF-1 inducibility of bovine, human, and mouse 4-kb and prox-
imal LOXL4 promoter luciferase constructs transfected into BAEC (Btau) and
MAEC (Mmus). (D) Effect of TGF-1 on LOXL4mRNA expression in BAEC
and MAEC as assessed by quantitative PCR. Values are represented as fold
induction with respect to basal levels in the absence of TGF-1 (mean	 SEM;
n
 3). *, P 0.05 versus the corresponding proximal promoter for luciferase
activity (C) or versus the basal value for mRNA expression (D).
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moter as assessed byChIP (validation of overexpression by adeno-
viral Fra2 and ChIP experiments is shown in Fig. S7A and B in the
supplemental material). Conversely, specific silencing of endoge-
nous Fra2 by siRNA technology significantly diminished the level
of induction of LOXL4 expression by TGF-1 (Fig. 5B) (valida-
tion of silencing by siRNA Fra2 is shown in Fig. S7C in the sup-
plemental material). Proteins belonging to the AP-1 family bind
DNA as obligate homo- or heterodimers.While Junmembers can
dimerize with each other and with Fos proteins, the members of
the Fos subfamily, c-Fos, FosB, and Fra1 and Fra2, cannot form
homodimers (37). To identify the Jun partner that dimerizes with
Fra2 in TGF-1-mediated activation of LOXL4 expression, we
took advantage of the existence of tetheredAP-1 dimers, including
JunB/Fra2, JunD/Fra2, and c-Jun/Fra2, with AP-1 molecules
joined via a flexible polypeptide tether to force specific pairing
(18). As shown in Fig. 5C, overexpression of forced JunB/Fra2
dimer resulted in a potentiation of TGF-1-induced promoter
activity, while Fra2/JunD and c-Jun/Fra2 did not show any signif-
icant effect, compared with empty vector (validation of the over-
expression of AP-1 dimers by anti-FlagWestern blotting is shown
in Fig. S7D in the supplemental material). The involvement of
JunB was further confirmed by siRNA experiments. Specific
downregulation of JunB expression resulted in a significant reduc-
tion of the effect of TGF-1 on LOXL4 promoter activity, whereas
the silencing of JunD and c-Jun did not have a significant effect
(Fig. 5D) (validation of silencing of Jun proteins by siRNA is
shown in Fig. S7E in the supplemental material).
Experiments involving Fra2 were done with an anti-Fra2 anti-
FIG 4 Involvement of Smad and AP-1 transcription factors in the effect of TGF-1 on LOXL4 expression. (A) Luciferase activity of LOXL4 promoter luciferase
constructs cotransfected with increasing amounts of Smad3 or Smad7 overexpression plasmids. (B) Wild-type and Smad3 knockout (KO) mouse embryonic
fibroblasts (MEF) were transfected with the LOXL4 promoter together with Smad3 plasmid. (C and D) Effect of adenovirus-mediated overexpression of the
dominant negative form of AP-1, TAM67 (108 to 109 PFU/ml) on TGF-1-mediated induction of LOXL4 mRNA (C) and promoter activity (D). Values are
represented as normalized units for luciferase activity and as fold induction with respect to basal values for mRNA expression (mean	 SEM; n
 3). *, P 0.05
versus pcDNA3 empty vector () (A and B, right panel), versus basal levels in the absence of TGF-1 stimulation (B, left panel), or versus empty vector null
adenovirus (C and D).
FIG 5 Involvement of Fra2 in the effect of TGF-1 on LOXL4 expression. (A) Adenovirus-mediated overexpression of Fra2 potentiates the action of TGF-1
on LOXL4 expression as assessed by luciferase reporter andWestern blotting. (B) siRNA-mediated downregulation of Fra2 inhibits TGF-1-mediated induction
of LOXL4 expression. (C) Effect of overexpression of forced AP-1 dimers, including JunB/Fra2, JunD/Fra2, and c-Jun/Fra2, on TGF-1-induced LOXL4
promoter activity. (D) Effect of siRNA-mediated downregulation of Jun members (JunB, JunD, and c-Jun) on TGF-1-induced LOXL4 promoter activity.
Values are represented either as fold inductionwith respect to basal values with null adenovirus or siRNA control or as normalized luciferase units (mean	 SEM;
n
 3), *, P 0.05 versus null adenovirus or empty vector (A andC), or versus siRNA control (B andD), in the presence of TGF-1. Validation of overexpression
or siRNA-mediated downregulation is shown in Fig. S7 in the supplemental material.
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body raised against mouse Fra2 protein, which unfortunately did
not reactwith the endogenous Fra2 frombovine aortic endothelial
cells but very efficiently recognized the overexpressed mouse iso-
form. Using this antibody in overexpression experiments, we no-
ticed that the reactivity of Fra2 bands increased significantly upon
TGF-1 stimulation, an observation that was accompanied by the
detection of higher-molecular-weight (higher-MW) immunore-
active bands (Fig. 6A; see Fig. S7A in the supplemental material).
Immunofluorescence experiments performed with the same pro-
tocol showed specific nuclear Fra2 staining that strongly increased
after TGF-1 incubation (see Fig. S7B in the supplemental mate-
rial). Protein phosphorylation may be compatible with the ob-
served changes in immunoreactivity and MW, and as such it is a
posttranslational modification previously reported for Fra2 (38,
39). To demonstrate the potential use of this antibody to reveal
phosphorylated Fra2 and therefore the ability of TGF-1 to in-
duce the phosphorylation of this factor, cell extracts were incu-
batedwith calf intestine alkaline phosphatase (CIAP) and -phos-
phatase (-PPase), conditions shown to dephosphorylate serine,
threonine, and tyrosine residues in proteins (40). As shown also in
Fig. 6A, dephosphorylation of cell extracts diminished signifi-
cantly the increase in immunoreactivity, an effect particularly ev-
ident with -phosphatase, and, more interestingly, eliminated the
higher-MW Fra2 bands, which presumably correspond to heavily
phosphorylated forms of the protein. The noncanonical TGF-
signaling pathway has been associatedwith the activation ofmem-
bers of themitogen-activated protein kinase (MAPK) family (30).
Screening of the sequences of the Fra2 protein among different
species, including mouse, rat, human, bovine, chicken, and
zebrafish, revealed the presence of two MAPK phosphorylation
consensus sites (P-X-X-S/T-P or P-X-S/T-P), in particular, two
threonine residues in the C-terminal domain (T263 and T274 in
the mouse Fra2), highly conserved in most of Fra2 orthologs and
in human and mouse c-Fos proteins (Fig. 6B). Flag-tagged Fra2
constructs with inactivating mutations of threonine to nonphos-
phorylatable alanine were generated, and the pattern of Flag-
tagged Fra2 expression uponTGF-1 stimulationwas analyzed by
SDS-PAGE and anti-Flag Western blotting. As shown in Fig. 6C,
the T274A substitution resulted in a clear decrease in the detection
of high-MW, hyperphosphorylated bands that otherwise were ob-
served with the wild type and the T263A mutant. The construct
including both mutations behaved essentially like the T274Amu-
tant. As an alternative approach, glutamic acid substitution mu-
tagenesis, a modification mimicking the structure of a phosphor-
ylated threonine residue, was also introduced. Figure 6C shows
that the T274E and, to a lesser extent, T263E substitutions shifted
the detected immunoreactive bands into high-MW forms, an ef-
fect more clearly evident in the double mutant. These results in-
dicate that phosphorylation of Fra2 in these residues, particularly
in the highly conserved T274, may play an important role in the
action of TGF-1. In order to test the ability of the Fra2mutants to
induce TGF-1-induced LOXL4 expression, we cotransfected
wild-type, T263/274A (inactivating), and T263/274E (phospho-
mimetic) Fra2 plasmids together with the LOXL4 promoter lucif-
erase construct. As shown also in Fig. 6D, the overexpression of
wild-type or T263/274E Fra2 strongly potentiated TGF-1-in-
duced LOXL4 promoter activity, whereas the mutant T263/274A
was without any effect. We have also investigated the mecha-
nism(s) bywhich Fra2 phosphorylation gives rise to a potentiation
of LOXL4 expression. First, we analyzed whether the interaction
of JunB/Fra2 complex with DNA is affected by Fra2 phosphoryla-
tion. In vitro-synthesized JunB/Fra2 forced dimers, either wild
type, T263/274A, or T263/274E, showed very similar DNA bind-
ing activity as assessed by EMSA (see Fig. S8A and B in the sup-
FIG 6 TGF-1 promotes the phosphorylation of Fra2. (A) Protein extracts from BAEC infected with null or Fra2 adenoviruses and stimulated with TGF-1 or
basal were either left untreated or preincubatedwith calf intestinal alkaline phosphatase (CIAP) (1 unit/g protein) or with-phosphatase (-PPase) (3 units/g
protein) for 1 h, followed by detection of Fra2 byWestern blotting. Note that high-MW bands were eliminated with CIAP and -PPase, likely corresponding to
hyperphosphorylated forms. (B) Domain structure of mouse Fra2 protein. Sequences from several Fra2 and c-Fos orthologs were aligned to show the conserved
motifs for MAPK consensus phosphorylation sites (*). Note that the mouse T274-containing motif is conserved among all species compared in this study,
whereas T263 is partially conserved in some Fra2 orthologs and in human and mouse c-Fos. (C) Analysis of electrophoretic mobility of Flag-tagged Fra2 with
point mutations in MAPK consensus phosphorylation sites T263 and T274. Single and double inactivating T¡A or phosphomimetic T¡E mutant constructs
were transiently transfected into bovine aortic endothelial cells with and without TGF-1 incubation, and protein extracts were analyzed by Western blotting
using an anti-Flag antibody. (D) Luciferase activity of LOXL4 promoter luciferase construct cotransfected with wild-type, T263/274A, and T263/274E Fra2
overexpression plasmids. Values are represented as normalized units for luciferase activity (mean	 SEM; n
 3). *, P 0.05 versus pcDNA3 empty vector ()
in the presence of TGF-1.
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plemental material). We next investigated whether Fra2 phos-
phorylation facilitates JunB/Fra2 dimerization using GST-Fra2
forms in pulldown experiments. As shown in Fig. S8C in the sup-
plemental material (input), JunB expression was induced upon
TGF-1 stimulation in BAEC, a result that was also observed by
microarray analysis (GEO accession number GSE42932). GST-
Fra2 beads were incubated with total extracts from BAEC incu-
bated under basal conditions or with TGF-1 for 24 h, extensively
washed, and loaded onto SDS-polyacrylamide gels for Western
blot analysis of JunB. GST-Fra2, either wild type, T263/274A, or
T263/274E, pulled down endogenous JunB protein with similar
capacities. These results indicate that Fra2 phosphorylation does
not significantlymodifyDNAbinding activity or dimer formation
of AP-1 complexes.
TGF-1-dependent Fra2 phosphorylation likely involves
the activation of a MAPK. We next analyzed the effects of spe-
cific pharmacological inhibitors of p38, ERK, and JNK MAPKs
on the upregulation of LOXL4 promoter activity by TGF-1.
As shown in Fig. 7A, the blockade of the ERK pathway strongly
attenuated the action of TGF-1, whereas the inhibitors of p38
and JNK did not show any significant effect. Dose-dependent
analysis of the effect of the ERK inhibitor, CI-1040, showed
that this compound diminished TGF-1-induced LOXL4
mRNA and promoter activity at concentrations reported to
specifically inhibit ERK phosphorylation (100 to 500 nM) (Fig.
7B and C) (41). We also studied the time course of the effect of
TGF-1 on ERK and Fra2 phosphorylation by Western blot-
ting. TGF-1 very rapidly induced an increase in the phos-
phorylation status of ERK, which was followed by the detection
of hyperphosphorylated forms of Fra2 (Fig. 7D). Both actions
of TGF-1 were strongly abolished by preincubation of the
ERK inhibitor. These results indicate that TGF-1 induction of
LOXL4 expression requires the activation of the ERK pathway
and subsequent ERK-dependent phosphorylation of Fra2.
LOXL4 contributes to the matrix remodeling action of
TGF-1 in aortic endothelial cells. LOXL4 is the most recently
identified member of the lysyl oxidase family. Therefore, little in-
formation is available on LOXL4 subcellular localization and
function, particularly in the cardiovascular system (42–44). The
C-terminal region of LOXL4 protein contains a catalytic domain
highly homologous to other lysyl oxidases. On the other hand, the
N-terminal region has four scavenger receptor cysteine-rich
(SRCR) domains that are conserved only in the LOXL2 and
LOXL3 isoforms. To gain insight into the subcellular localization
of LOXL4 protein and to individually analyze the contributions of
its different domains, we generated a LOXL4-GFP fusion protein
and deletion mutants thereof lacking the SRCR domains and the
C-terminal catalytic region (Fig. 8A). Cell transfection with the
full-length LOXL4-GFP construct showed that the fluorescent sig-
nal was perinuclear, spatially overlapping with the immunocyto-
chemical detection of calnexin, a typical endoplasmic reticulum
(ER) marker (Fig. 8B). This subcellular distribution is roughly
maintained upon removal of the SRCR domains, but it is heavily
affected by deletion of the C-terminal catalytic region, whose flu-
orescence was homogeneously diffuse throughout the cell, much
in the same way as GFP only (see Fig. S9 in the supplemental
material). The localization of the full-length protein in the ER
compartment suggests that LOXL4 may transit through the ER as
a part of the secretory pathway, yielding its release into the extra-
cellular medium. To evaluate this hypothesis, we generated stable
transfectants of human embryonic kidney 293 (HEK 293) cells
expressing the aforementioned set of LOXL4-GFP constructs.
Analysis by anti-GFPWestern blotting showed that these isogenic
clones of HEK 293 cells expressed the corresponding LOXL4-GFP
proteins (Fig. 8C, Cells). The extracellular medium accumulated
for 48 h was concentrated and analyzed by Western blotting. As
shown also in Fig. 8C (Media), full-length LOXL4-GFPwas clearly
detectable in the extracellular medium, indicating that this pro-
tein is indeed extracellularly secreted. The presence of multiples
copies of the SCRC domains seems to be essential for the extracel-
lular release, as elimination of more than one of these repeats
impaired the accumulation of the protein in the extracellular me-
dium. LOXL4-GFP C-t, a deletion construct with intact SRCR
domains, was again recovered from the extracellular medium.
Similar experiments performed with BAEC incubated with
TGF-1 or infectedwith a LOXL4-overexpressing adenovirus also
FIG 7 TGF-1 induces LOXL4 expression by ERK-mediated phosphoryla-
tion of Fra2. (A) Effects of MAPK inhibitors SB203580 (p38, 10M), CI-1040
(ERK, 2 M), and SP600125 (JNK, 25 M) on luciferase activity of LOXL4
promoter luciferase construct. Values are represented as normalized luciferase
units (mean 	 SEM; n 
 3). *, P  0.05 versus vehicle (dimethyl sulfoxide
[DMSO] for SB203580 and CI-1040 and ethanol for SP600125) upon TGF-1
stimulation. (B and C) Dose dependence analysis of the effect of the ERK
inhibitor CI-1040 on TGF-1-induced LOXL4 promoter activity (B) and
mRNA expression (C). (D) Time course of the effect of TGF-1 on ERK
activation (phospho-ERK [p-ERK]) and Fra2 phosphorylation (p-Fra2) ana-
lyzed by Western blotting in extracts from cells treated with vehicle (control)
or withCI-1040 (2M).Values above the blots refer to the p-Fra2/-actin and
p-ERK/total ERK ratios after densitometric analysis. Results are representative
of three experiments.
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showed the presence of extracellularly secreted LOXL4 protein
(Fig. 8D).
To explore the contribution of LOXL4 to collagen cross-link-
ing, we incubated soluble type I collagen with conditioned me-
diumgenerated by aortic endothelial cells incubated for 48 h in the
presence or absence of TGF-1 and with empty vector or LOXL4-
overexpressing adenoviruses, and fibrillar collagen was imaged by
confocal reflection microscopy. As shown in Fig. 9A, based on
fiber size, fibrillar collagen formation was strongly enhanced in
samples incubated withmedium from cells exposed to TGF-1 or
infected with LOXL4 adenovirus. This matrix-remodeling capac-
ity was consistent with the classical determination of lysyl oxidase
activity by detection of H2O2 using Amplex red as assessed in both
endothelial cells and HEK 293 cells overexpressing LOXL4 (Fig.
9B). The ability of LOXL4 to regulate the deposition and assembly
of collagen IV was analyzed by immunofluorescence microscopy.
As shown in Fig. 9C, cells overexpressing LOXL4 showed in-
creased collagen IV network assembly compared to control cells.
These data suggest that LOXL4 may play a role in collagen IV
assembly in the subendothelial basement membrane, therefore
contributing significantly to vascular extracellular microenviron-
ment.
DISCUSSION
The role of LOX enzymes in humanpathophysiology has attracted
considerable interest in recent years, as elevated expression and/or
activity has been associated with several diseases, particularly of
the vascular system, and with tumorigenesis (45, 46). As long as
biological mechanisms for the control of LOX activity remain un-
known, the main point of regulation is the control of the expres-
sion of LOX family members. TGF-1 has revealed as an impor-
tant factor for the regulation of the expression of LOX isoforms in
different cells and tissues (47–49). LOXL4 has also been recently
described to be upregulated byTGF- signaling in hepatoma cells,
though the exact molecular mechanism for this action was not
studied in depth (26). The present work describes in detail, to our
knowledge for the first time, the regulation of the expression of
LOXL4 by TGF-1 in bovine aortic endothelial cells. According to
our results, transcriptional activation of the LOXL4 promoter ac-
counted for the TGF-1-induced increase in LOXL4 expression.
We have identified a genomic region at about 4 kb upstreamof the
transcription initiation site that is responsible for the effect of
FIG 8 Subcellular localization and extracellular secretion of LOXL4 in
aortic endothelial cells. (A) Domain structure of full-length (FL) LOXL4-
GFP fusion protein and deletion mutants thereof lacking the SRCR do-
mains and the C-terminal catalytic region. (B) Subcellular localization of
full-length LOXL4-GFP expressed in bovine aortic endothelial cells by ad-
enoviral infection as assessed by GFP fluorescence microscopy (upper
panel) and colocalization of the endoplasmic reticulummarker calnexin by
immunofluorescence (lower panel). (C) Analysis of the extracellular secre-
tion of LOXL4-GFP chimeras stably expressed in HEK 293 cells byWestern
blotting using anti-GFP antibody. Note the presence of secreted GFP-im-
munoreactive bands in FL, SRCR1, and C-t. (D) Extracellular secretion
of endogenous LOXL4 upon TGF-1 incubation in aortic endothelial cells
as assessed by Western blotting with anti-LOXL4 antibody. The secretion
of LOXL4-GFP from cells infected with the corresponding adenovirus is
also shown (Media, supernatant; Cells, cell extract). Results are represen-
tative of three experiments.
FIG 9 LOXL4 expression leads to matrix remodeling. (A) Type I collagen
solution was mixed with medium from cells left under basal conditions, ex-
posed to TGF-1, or infected with LOXL4 or null adenoviruses, and fibrillar
collagen formation was monitored by confocal reflection microscopy. Colla-
gen fiber number and size were counted in at least three random fields and
represented as number of fibers per range of size. (B) Lysyl oxidase activity as
assessed by H2O2 Amplex determination in supernatants from BAEC with or
without TGF-1 stimulation or infected with Ad-LOXL4 and inHEK 293 cells
treated with or without doxycycline (Dox). A positive control with recombi-
nant human LOXL2 is also shown. (C) Increased collagen IV deposition and
assembly by BAEC infected with adeno-LOXL4 compared with adeno-null
visualized by immunofluorescencemicroscopy. Results are representative of at
least three experiments.
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TGF-1. This genomic fragment, which behaves as a sensitive
TGF-1-activated enhancer, contains specific binding sites for
AP-1 and Smad transcription factors. Specific mutation of these
elements abolished TGF-1 responsiveness, as well as the binding
activity of these factors. The cooperation between Smad and AP-1
transcription factors is essential to determine TGF- signaling to
the nucleus, and examples from the literature include the genes
encoding endothelin 1 (ET-1), follicle-stimulating hormone 
(FSHB), and tumor necrosis factor-related apoptosis-inducing li-
gand (TRAIL), among others (12, 50, 51). In fact, AP-1 sites have
been shown to be the most enriched motif in Smad2/3 regions
identified recently in a ChIP-on-chip analysis (52). Interestingly,
this report successfully identified the enhancer within the LOXL4
promoter characterized here as a Smad2/3 binding region in
HaCaT cells, and it proposed LOXL4 as a TGF--inducible gene.
Comparative sequence analysis of 5= flanking regions of mamma-
lian LOXL4 orthologs showed that this region indeed is evolution-
arily well conserved, with the AP-1 site and the Smad binding
elements present in most mammalian genomes. Surprisingly, the
AP-1 site was not conserved in rodent orthologs, and this obser-
vation is consistent with the lack of response to TGF-1 by the
mouse LOXL4 gene. These results indicate that selective con-
straints acting on this region may have been relaxed in the mouse
and rat species, as is estimated to have occurred with 30 to 40% of
the human functional sites, an aspect raising concerns about the
generalization of the regulation of expression and likely also of the
function of LOXL4 in the rodent models (53).
The present work identified Fra2 as the AP-1 component in-
teracting with the AP-1 site within the LOXL4 promoter and con-
tributing to the action of TGF-1 on LOXL4 expression. This
finding further supports the notion that Fra2 may act as a novel
downstream mediator of the effect of TGF-1 on matrix remod-
eling and fibrosis. Strong expression of Fra2 was detected in lung
samples from patients with idiopathic pulmonary fibrosis (33).
Additionally, Fra2 was found to be overexpressed in the dermis of
patients with scleroderma, where it has been proposed to play a
role in the induction of ECM proteins upon TGF-1 stimulation
(34, 36). Transgenic mice overexpressing Fra2 develop extensive
fibrosis in several organs, with the pulmonary tissue being partic-
ularly affected, which is initiated as a severe vasculopathy charac-
terized by vascular remodeling and obliteration of pulmonary ar-
teries (35). Based on these observations and our own results in
vascular endothelial cells, it can be hypothesized that Fra2 medi-
ates a specific TGF-1-dependent, ECM-specific genetic program
in the vasculature, which can eventually contribute to the devel-
opment of fibrosis. Experiments in dermal fibroblasts from sclero-
derma patients have also shown that the inhibition of the ERK
pathway impairs Fra2-dependent collagen production (36). In
fact, ERK has been largely implicated in the activation of fibrotic
responses, both in the skin and in the cardiovascular system, and
in agreement with our results, this kinase is phosphorylated and
activated upon stimulation with TGF-1 (54–56). We also report
here that TGF-1 promotes the ERK-dependent phosphorylation
of Fra2 and, based on mutagenesis experiments, identified T274
and (to a lesser extent) T263 as the phosphorylation sites ofmouse
Fra2 required to promote TGF-1-dependent LOXL4 expression.
The mechanism by which Fra2 phosphorylation regulates gene
transcription seems not to involve increased DNA binding or
AP-1 complex formation.
Fra2 requires dimerization with a Jun partner in order to form
the AP-1 complex capable of binding DNA, and according to our
results, this role is supported by JunB. Recent reports have delin-
eated the essential role of JunB in TGF--induced fibrotic re-
sponses (57). In fact, JunB not only contributes tomatrix produc-
tion and deposition but is an integral part of the TGF--induced
epithelial-to-mesenchymal transition (EMT) process. Today it
has become clear that endothelial cells can also transition into
mesenchymal cells and that TGF-1 is a primary inducer of this
process (58, 59). The extent of this transdifferentiation correlates
with the acquisition of smoothmuscle cell (SMC)markers, poten-
tially serving this process as a source of smooth muscle cells in
vascular neointimal lesions (60, 61). Under our experimental con-
ditions, TGF-1 stimulation of bovine aortic endothelial cells did
not promote the expression of -smooth muscle actin (-SMA),
the bona fide marker of SMC differentiation, but we did observe
the induction of other SMC-specific genes, for example, those for
cysteine and glycine-rich protein 2 (CSRP2), transgrelin
(SM22), and ankyrin repeat domain 1 (ANKRD1) (see microar-
ray data) (62–64). It is tempting to speculate whether LOXL4may
also be assigned to the category of SMC genes contributing to
proliferation, migration, and matrix deposition and associated
with the development of intimal thickening and other vascular
pathologies.
TGF-1 activation of the endothelium, both under cell culture
conditions and in the native endothelium, has been also shown to
induce the formation of podosomes, which are specialized plasma
membrane actin-based microdomains endowed, in a manner
similar to that for invadopodia, with adhesive andmatrix-degrad-
ing activities (65, 66). Degradation of the underlying basement
membrane by podosome-localized proteases is associated with
vessel ECM remodeling and tissue invasion. It can be hypothe-
sized that basementmembrane proteolysis by podosomes and fur-
ther LOXL4-basedmatrix cross-linking constitute early (degrada-
tive) and late (reparative) responses of the endothelium to
TGF-1 stimulation, respectively. Type IV collagen polymers, the
predominant scaffolding of basement membranes, are stabilized
by a network of covalent cross-links (67). Unlike fibrillar collagens
(types I, II, III, V, and XI), where LOX-mediated cross-linking has
been largely demonstrated to occur, the implication of LOX fam-
ilymembers in the assembly of type IV collagen networks is still an
open question (68). The present work for LOXL4 and our recent
report for LOXL2 showed that these enzymes contribute signifi-
cantly to type IV collagen deposition in the ECM (69). These find-
ings indicate an active role for these enzymes in the assembly of
type IV collagen networks, further supporting the long-appreci-
ated observation that this type of collagen cannot be efficiently
extracted from basementmembranes assembled in vivo unless the
animals are fed a lathyrogen (i.e., a compound such as -amino-
propionitrile that inhibits LOX activity, therefore preventing col-
lagen cross-linking) (70).
Early reports on the biochemical properties of LOXL4 de-
scribed this protein as an extracellularly secreted factor (44). We
confirmed here this observation and further analyzed the role of
the SRCR domains in the release of the protein. Our results
showed unequivocally that SRCR domains are required for
LOXL4 to be detected in the extracellular medium. SRCR do-
mains constitute ancient and highly conserved protein modules
present in a number of soluble or membrane-bound proteins for
which no unifying function has been so far defined (71). A recent
report has shown that the enzymatic activity of LOXL2 is not
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altered upon deletion of SRCR domains (72). This observation
and our own results suggest that N-terminal SRCR-containing
domains and C-terminal catalytic region provide LOXL isoforms
with independent capabilities, with the former likely contributing
to protein secretion and the latter being responsible for the enzy-
matic activity.
In summary, we describe here the identification of the LOXL4
gene as a TGF-1 target gene in bovine aortic endothelial cells and
the characterization of the molecular mechanism utilized by this
cytokine to induce the expression of the LOXL4 gene. We show
that TGF-1 activates both canonical (Smad-dependent) and
noncanonical (Smad-independent, ERK-dependent) signaling
pathways, which require AP-1 and Smad sites identified within an
upstream TGF-1-activated enhancer in the LOXL4 promoter.
We also provide evidence that LOXL4 is extracellularly secreted
and significantly contributes in vitro to ECMdeposition. Based on
our results, we propose that TGF-1-dependent expression of
LOXL4 might have pathophysiological implications in vascular
processes associated with matrix remodeling and fibrosis.
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